Radical surgery and radiotherapy – purpose and results of these treatment options in patients with higher stage prostate cancer


Authors: V. Vít;  A. Čermák;  D. Pacík
Authors‘ workplace: Urologická klinika LF MU a FN Brno
Published in: Urol List 2014; 12(3): 32-39

Overview

Prostate cancer – one of the most common malignant tumours and cause of death in men – represents very significant medical but also social and economic problem. Diagnostics and ensuing treatment (both curative treatment and treatment of advanced stages, including associated complications) is a very complex process, not only for patients (because early detection of prostate cancer affects large numbers of men) but also for healthcare systems, because continuously increasing incidence and prevalence have significant organizational, HR and last but not at least economic demands. Owing to the heterogeneous nature of prostate cancer the optimal therapy is not clear. But we can try to determine the best treatment in an individual patient and assess if it is feasible and justified considering the individual prostate cancer stage. The author focuses on higher stage prostate cancer and higher risk groups and evaluates the feasibility and results of individual treatment options – radical surgery and radiotherapy.

Key words:
prostate cancer, radical prostatectomy, radiotherapy


Sources

1. Epidemiologie zhoubných nádorů v České republice. [online]. Dostupné z: www.svod.cz.

2. Bill‑ Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011; 364(18): 1708– 1717. doi: 10.1056/ NEJMoa1011967.

3. Wilt TJ, Brawer MK, Jones KM et al. Radical pros­tatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367(3): 203– 213. doi: 10.1056/ NEJMoa1113162.

4. Capitanio U, Scattoni V, Freschi M et al. Radical prostatectomy for incidental (stage T1a‑ T1b) pros­tate cancer: analysis of predictors for residual dis­ease and bio­chemical recurrence. Eur Urol 2008; 54(1): 118– 125. doi: 10.1016/ j.eururo.2008.02.018.

5. Lowe BA, Listrom MB. Incidental carcinoma of the prostate: an analysis of the predictors of progression. J Urol 1988; 140(6): 1340– 1344.

6. Elgamal AA, Van Poppel HP, Van de Voorde WM et al.Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical pros­tatectomy specimens –  a different view. J Urol 1997; 157(1): 244– 250.

7. Oesterling JE, Suman VJ, Zincke H et al. PSA‑ detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors. Urol Clin North Am 1993; 20(4): 687– 693.

8. Epstein JI, Walsh PC, Brendler CB. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle bio­psy (stage T1C). J Urol 1994; 152(5 Pt 2): 1721– 1729.

9. Singh H, Canto EI, Shariat SF et al. Improved detection of clinically significant, curable prostate cancer with systematic 12– core bio­psy. J Urol 2004; 171(3): 1089– 1092.

10. Epstein JI, Chan DW, Sokoll LJ et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/ total prostate specific antigen levels and needle bio­psy findings. J Urol 1998; 160(6 Pt 2): 2407– 2411.

11. Makarov DV, Trock BJ, Humphreys EB et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate‑ specific antigen level, clinical stage, and bio­psy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007; 69(6): 1095– 1101.

12. D’Amico AV, Whittington R, Malkowicz SB et al. Combination of the preoperative PSA level, bio­psy gleason score, percentage of positive bio­psies and MRI T‑stage to predict early PSA failure in men with clinically localized prostate cancer. Urology 2000; 55(4): 572– 577.

13. Epstein JI. Gleason score 2– 4 adenocarcinoma of the prostate on needle bio­psy: a dia­gnosis that should not be made. Am J Surg Pathol 2000; 24(4): 477– 478.

14. Epstein JI, Steinberg GD. The significance of low‑ grade prostate cancer on needle bio­psy. A radical prostatectomy study of tumor grade, volume, and stage of the bio­psied and multifocal tumor. Cancer 1990; 66(9): 1927– 1932.

15. Briganti A, Larcher A, Abdollah F et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 2012; 61(3): 480– 487. doi: 10.1016/ j.eururo.2011.10.044.

16. Graversen PH, Nielsen KT, Gasser TC et al. Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen‑year follow‑up. Urology 1990; 36(6): 493– 498.

17. Isbarn H, Wanner M, Salomon G et al. Long‑term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate‑ specific antigen era. BJU Int 2010; 106(1): 37– 43. doi: 10.1111/ j.1464‑ 410X.2009.09134.x.

18. Roehl KA, Han M, Ramos CG et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long‑term results. J Urol 2004; 172(3): 910– 914.

19. Han M, Partin AW, Pound CR et al. Long‑term bio­chemical disease‑free and cancer‑ specific survival following anatomic radical retropubic prostatectomy. The 15‑year Johns Hopkins experience. Urol Clin North Am 2001; 28(3): 555– 565.

20. Hull GW, Rabbani F, Abbas F et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167(2 Pt 1): 528– 534.

21. Porter CR, Kodama K, Gibbons RP et al. 25‑year prostate cancer control and survival outcomes: a 40‑year radical prostatectomy single institution series. J Urol 2006; 176(2): 569– 574.

22. Shao YH, Demissie K, Shih W et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst 2009; 101(18): 1280– 1283. doi: 10.1093/ jnci/ djp262.

23. Yossepowitch O, Eggener SE, Bianco FJ Jr et al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 2007; 178(2): 493– 499, discussion: 499.

24. Fallon B, Williams RD. Current options in the management of clinical stage C prostatic carcinoma. Urol Clin North Am 1990; 17(4): 853– 866.

25. Boccon‑ Gibod L, Bertaccini A, Bono AV et al. Management of locally advanced prostate cancer: a European consensus. Int J Clin Pract 2003; 57(3): 187– 194.

26. Bolla M, Collette L, Blank L et al. Long‑term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360(9327): 103– 106.

27. Gerber GS, Thisted RA, Chodak GW et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi‑institutional pooled analysis. Eur Urol 1997; 32(4): 385– 390.

28. Van Poppel H, Ameye F, Oyen R et al. Accuracy of combined computerized tomography and fine nee­dle aspiration cytology in lymph node staging of localized prostatic carcinoma. J Urol 1994; 151(5): 1310– 1314.

29. Van Poppel H, Vekemans K, Da Pozzo L et al. Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001). Eur J Cancer 2006; 42(8): 1062– 1067.

30. Ward JF, Slezak JM, Blute ML et al. Radical pros­tatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate‑ specific antigen test­ing: 15‑year outcome. BJU Int 2005; 95(6): 751– 756.

31. Carver BS, Bianco FJ Jr, Scardino PT et al. Long‑term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 2006; 176(2): 564– 568.

32. Hsu CY, Joniau S, Oyen R et al. Outcome of surgery for clinical unilateral T3a prostate cancer: a single‑institution experience. Eur Urol 2007; 51(1): 121– 128, discussion: 128– 129.

33. Van Poppel H, Joniau S. An analysis of radical pros­tatectomy in advanced stage and high‑grade prostate cancer. Eur Urol 2008; 53(2): 253– 259.

34. Joniau S, Hsu CY, Lerut E et al. A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a pros­tate cancer. Eur Urol 2007; 51(2): 388– 394, discus­sion: 395– 396.

35. Loeb S, Smith ND, Roehl KA et al. Intermediate‑ -term potency, continence, and survival outcomes of radical prostatectomy for clinically high‑risk or lo­cally advanced prostate cancer. Urology 2007; 69(6): 1170– 1175.

36. D’Amico AV, Whittington R, Malkowicz SB et al. Pretreatment nomogram for prostate‑ specific antigen recurrence after radical prostatectomy or external‑ beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999; 17(1): 168– 172.

37. Spahn M, Joniau S, Gontero P et al. Outcome predictors of radical prostatectomy in patients with prostate‑ specific antigen greater than 20 ng/ ml: a European multi‑institutional study of 712 patients. Eur Urol 2010; 58(1): 1– 7, discussion: 10– 11. doi: 10.1016/ j.eururo.2010.03.001.

38. Gontero P, Spahn M, Tombal B et al. Is there a pros­tate‑ specific antigen upper limit for radical prostatectomy? BJU Int 2011; 108(7): 1093– 1100. doi: 10.1111/ j.1464‑ 410X.2011.10076.x.

39. Johnstone PA, Ward KC, Goodman M et al. Radical prostatectomy for clinical T4 prostate cancer. Cancer 2006; 106(12): 2603– 2609.

40. Gontero P, Marchioro G, Pisani R et al. Is radical prostatectomy feasible in all cases of locally advanced non‑bone metastatic prostate cancer? Results of a single‑institution study. Eur Urol 2007; 51(4): 922– 929, discussion: 929– 930.

41. Ghavamian R, Bergstralh EJ, Blute ML et al. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol 1999; 161(4): 1223– 1227, discussion: 1277– 1278.

42. Messing EM, Manola J, Yao J et al. Immediate versus deferred androgen deprivation treatment in patients with node‑ positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7(6): 472– 479.

43. Engel J, Bastian PJ, Baur H et al. Survival benefit of radical prostatectomy in lymph node‑ positive patients with prostate cancer. Eur Urol 2010; 57(5): 754– 761. doi: 10.1016/ j.eururo.2009.12.034.

44. Bolla M, Van Tienhoven G, Warde P et al. External irradiation with or without long‑term androgen sup­pression for prostate cancer with high metastatic risk: 10‑year results of an EORTC randomised study. Lancet Oncol 2010; 11(11): 1066– 1073. doi: 10.1016/ S1470‑ 2045(10)70223‑ 0.

45. Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma –  long‑term results of phase IIIRTOG 85– 31. Int J Radiat Oncol Biol Phys 2005; 61(5): 1285– 1290.

46. Roach M 3rd, Bae K, Speight J et al. Short‑term neoadjuvant androgen deprivation therapy and external‑ beam radiotherapy for locally advanced prostate cancer: long‑term results of RTOG 8610. J Clin Oncol 2008; 26(4): 585– 591. doi: 10.1200/ JCO.2007.13.9881.

47. Krauss D, Kestin L, Ye H et al. Lack of benefit for the addition of androgen deprivation therapy to dose‑escalated radiotherapy in the treatment of intermediate‑  and high‑risk prostate cancer. Int J Radiat Oncol Biol Phys 2011; 80(4): 1064– 1071. doi: 10.1016/ j.ijrobp.2010.04.004.

48. Kupelian PA, Ciezki J, Reddy CA et al. Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2008; 71(1): 16– 22.

49. Warde P, Mason M, Ding K et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011; 378(9809): 2104– 2111. doi: 10.1016/ S0140‑ 6736(11)61095‑ 7.

50. Mason M, Warde P, Sydes M et al. Defining the need for local therapy in locally advanced prostate cancer: an appraisal of the MRC PR07 study. Clin Oncol (R Coll Radiol) 2005; 17(4): 217– 218.

51. Widmark A, Klepp O, Solberg A et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG‑ 7/ SFUO‑ 3): an open randomised phase III trial. Lancet 2009; 373(9660): 301– 308. doi: 10.1016/ S0140‑ 6736(08)61815‑ 2.

52. Hanks GE. External‑ beam radiation therapy for clinically localized prostate cancer: patterns of care studies in the United States. NCI Monogr 1988; (7): 75– 84.

53. Swanson GP, Thompson IM. Adjuvant radiotherapy for high‑risk patients following radical prostatectomy. Urol Oncol 2007; 25(6): 515– 519.

54. Bolla M, van Poppel H, Tombal B et al. Postoperative radiotherapy after radical prostatectomy for high‑risk prostate cancer: long‑term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012; 380(9858): 2018– 2027. doi: 10.1016/ S0140‑ 6736(12)61253‑ 7.

55. Wiegel T, Bottke D, Steiner U et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate‑ specific antigen: ARO 96– 02/ AUO AP 09/ 95. J Clin Oncol 2009; 27(18): 2924– 2930. doi: 10.1200/ JCO.2008.18.9563.

56. Swanson GP, Thompson IM, Tangen C et al. Update of SWOG 8794: adjuvant radiotherapy for pT3 prostate cancer improves metastasis free survival. Int J Radiat Oncol Biol Phys 2008; 72: S31.

57. Thompson IM, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathological T3N0M0 pros­tate cancer significantly reduces risk of metastases and improves survival: long‑term followup of a randomized clinical trial. J Urol 2009; 181(3): 956– 962. doi: 10.1016/ j.juro.2008.11.032.

58. Stephenson AJ, Scardino PT, Kattan MW et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical pros­tatectomy. J Clin Oncol 2007; 25(15): 2035– 2041.

59. Siegmann A, Bottke D, Faehndrich J et al. Salvage radiotherapy after prostatectomy –  what is the best time to treat? Radiother Oncol 2012; 103(2): 239– 243. doi: 10.1016/ j.radonc.2011.10.024.

60. Ataman F, Zurlo A, Artignan X et al. Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863. Eur J Cancer 2004; 40(11): 1674– 1681.

61. Robinson JW, Moritz S, Fung T. Meta‑analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys 2002; 54(4): 1063– 1068.

62. Baxter NN, Tepper JE, Durham SB et al. Increased risk of rectal cancer after prostate radiation: a population‑based study. Gastroenterology 2005; 128(4): 819– 824.

63. Liauw SL, Sylvester JE, Morris CG et al. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow‑up. Int J Radiat Oncol Biol Phys 2006; 66(3): 669– 673.

64. Zelefsky MJ, Eastham JA, Cronin AM et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 2010; 28(9): 1508– 1513. doi: 10.1200/JCO.2009.22.2265.

Labels
Paediatric urologist Urology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account